ArticleBMC medicine2026
The impact of shielding on COVID-19 hospitalisations and deaths during 2020 in England: a transmission modelling evaluation using the OpenSAFELY platform.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDuring the early phase of the COVID-19 pandemic in England, people with pre-existing conditions at severe clinical risk were advised to drastically reduce face-to-face contacts in a policy known as "shielding". The impact of shielding in preventing COVID-19 hospitalisations and deaths has not been evaluated nationally using transmission-dynamic modelling.
methodsWith the approval of NHS England, we present a retrospective cohort evaluation of the shielding policy, drawing data from electronic health records (EHRs) for 24 million patients in England accessed through the OpenSAFELY platform. The study is from 1 January-1 December 2020, prior to vaccination and SARS-CoV-2 variants. We used a dynamic model of SARS-CoV-2 transmission, infection, and hospitalisation, stratified by age and shielding status for the general population (excluding care homes). We estimated transmission rates in the shielding and non-shielding groups using data from the CoMix social contact survey and fitted the model to hospitalisations and deaths in and outside hospital.
resultsWe found the risk of hospitalisation was higher for shielding people at all ages and increased with age. The hospitalisation fatality risk was similar between shielding and non-shielding people from January to June 2020 and greater in shielding people from July 2020 onward. By comparing the observed epidemic to a counterfactual scenario without shielding, we projected that between 7800 and 10,600 hospitalisations and 2300 to 3500 deaths due to COVID-19 were directly averted by the policy, corresponding to reductions of 25% (24, 28%) and 23% (21, 25%), respectively, in the shielding population in England up to 1 December 2020. Including also the indirect effect in the non-shielding population, we projected 14,700 - 21,800 hospitalisations and 3700-5500 deaths due to COVID-19 were averted by the policy in the total population, each corresponding to reductions of 13% (11, 16%).
conclusionsBased on our data and assumptions, we estimated the shielding policy reduced severe illness and mortality in clinically-extremely vulnerable shielding patients in England up to 1 December 2020, and, through indirectly-reduced exposure, also in the non-shielding population. Similar policies for other infections could have a comparable public health impact in reducing both mortality and pressure on health services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.